IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation
Liu, Qifa1; Xuan, Li1; Liu, Hui1; Huang, Fen1; Zhou, Hongsheng1; Fan, Zhiping1; Zhao, Ke1; Wu, Meiqing1; Xu, Lanping2; Zhai, Xiao1; Zhang, Fuhua1; Liu, Can1; Sun, Jing1; Huang, Xiaojun2
刊名AMERICAN JOURNAL OF HEMATOLOGY
2013-07-01
DOI10.1002/ajh.23452
88期:7页:550-555
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
资助者National High Technology Research and Development Program of China (863 Program) ; National Public Health Grand Research Foundation ; National Natural Science Foundation of China ; Science and Technology Project of Guangdong Province of China ; Medical Scientific Research Foundation of Guangdong Province ; Guangdong Natural Science Foundation ; National High Technology Research and Development Program of China (863 Program) ; National Public Health Grand Research Foundation ; National Natural Science Foundation of China ; Science and Technology Project of Guangdong Province of China ; Medical Scientific Research Foundation of Guangdong Province ; Guangdong Natural Science Foundation
研究领域[WOS]Hematology
关键词[WOS]POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE ; POLYMERASE-CHAIN-REACTION ; VERSUS-HOST-DISEASE ; HIGH-RISK PATIENTS ; VIRAL LOAD ; HEMATOLOGICAL MALIGNANCIES ; EBV REACTIVATION ; DISORDERS ; RITUXIMAB ; RECIPIENTS
英文摘要

The optimal preemptive therapy for Epstein-Barr virus (EBV)-associated diseases remains under discussion. We developed a stepwise preemptive therapy (antiviral agents and reduction of immunosuppressants [RI] followed by rituximab) for EBV viremia, based on duration of EBV viremia and changes of viral loads. The blood EBV-DNA loads were regularly monitored by quantitative real-time polymerase chain reaction in 251 recipients undergoing allogeneic stem cell transplantation. The 3-year cumulative incidence of EBV viremia and EBV-associated diseases were 31.1%+/- 3.1% and 15.6%+/- 2.5%, which rose steeply with greater numbers of major risk factors. Of the 64 patients undergoing first-step preemption, 24 achieved complete response (CR) and 40 showed no response, including 25 progressing to EBV-associated diseases. The effective rates of antiviral agents and RI plus antiviral agents were 2/16 and 22/48 (P=0.017). Fourteen achieved CR and one progressed to lymphoproliferative disease in the 15 patients undergoing rituximab preemption. Of the 26 patients progressing to EBV-associated diseases during preemptive therapy, 20 obtained CR in the 23 cases with rituximab-based treatments. The preemptive efficacy of RI plus antiviral agents was correlated with the numbers of major risk factors (rs=-0.298; P=0.04). B-cell reconstitution was significantly delayed for at least 6 months in patients with rituximab preemption. The risk of herpesvirus infection was similar in patients who showed effective progress to first-step and rituximab preemption (P=0.094). RI plus antiviral agents could be given priority to low-risk patients, whereas more frequent monitoring of blood EBV-DNA and earlier preemptive rituximab should be advocated in high-risk patients. Am. J. Hematol. 88:550-555, 2013. (c) 2013 Wiley Periodicals, Inc.

语种英语
所属项目编号2011AA020105 ; 201202017 ; 81000231 ; 81270647 ; 81200388 ; 30971300 ; 2009A030200007 ; 2012B031800403 ; A2010010 ; 10451008004004158
资助者National High Technology Research and Development Program of China (863 Program) ; National Public Health Grand Research Foundation ; National Natural Science Foundation of China ; Science and Technology Project of Guangdong Province of China ; Medical Scientific Research Foundation of Guangdong Province ; Guangdong Natural Science Foundation ; National High Technology Research and Development Program of China (863 Program) ; National Public Health Grand Research Foundation ; National Natural Science Foundation of China ; Science and Technology Project of Guangdong Province of China ; Medical Scientific Research Foundation of Guangdong Province ; Guangdong Natural Science Foundation
WOS记录号WOS:000320662200003
Citation statistics
Cited Times:13[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66884
Collection北京大学第二临床医学院_血液科
作者单位1.Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China
2.Peking Univ Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
Recommended Citation
GB/T 7714
Liu, Qifa,Xuan, Li,Liu, Hui,et al. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation[J]. AMERICAN JOURNAL OF HEMATOLOGY,2013,88(7):550-555.
APA Liu, Qifa.,Xuan, Li.,Liu, Hui.,Huang, Fen.,Zhou, Hongsheng.,...&Huang, Xiaojun.(2013).Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.AMERICAN JOURNAL OF HEMATOLOGY,88(7),550-555.
MLA Liu, Qifa,et al."Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation".AMERICAN JOURNAL OF HEMATOLOGY 88.7(2013):550-555.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Liu, Qifa]'s Articles
[Xuan, Li]'s Articles
[Liu, Hui]'s Articles
百度学术
百度学术Similar articles in
[Liu, Qifa]'s Articles
[Xuan, Li]'s Articles
[Liu, Hui]'s Articles
必应学术
必应学术Similar articles in
[Liu, Qifa]'s Articles
[Xuan, Li]'s Articles
[Liu, Hui]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.